Cell and gene therapies promise to transform patient outcomes by unlocking cures for diseases with high-unmet need. Yet, their complex nature presents therapy owners with unprecedented challenges across logistics, commercialization, market access, and reimbursement that threaten to derail a product’s success.

In this white paper, market-leading experts from AmerisourceBergen, TrakCel and Invetech propose action-oriented solutions to cell and gene therapy commercialization, including what it takes to design and execute an effective commercialization strategy.

Download this white paper for key takeaways related to:

  • cGMP manufacturing
  • Securing regulatory approval
  • Integrating supply chain and logistics strategy
  • Critical success factors for market access
  • Creating a differentiated patient and provider experience
  • Managing payment and distribution

Authors & Contributors:


Download the Guide

Let’s create tomorrow’s cell and gene therapy solutions

Invetech helps cell and gene therapy developers to visualize, strategize and manage the future. With proven processes, expert insights and full-spectrum services, we swiftly accelerate vital, emerging therapies from the clinic to commercial-scale manufacturing. Together with our partners, we expand the reach of next-generation medical advances that are revolutionizing healthcare. Learn more at invetechgroup.com

Organovo logo-2
Humacyte logo-2